Sentinel Node Localization in Breast Cancer Patients Using Intradermal Dye Injection

Authors

  • Lars Ilum From the Departments of Surgery A, Odense, Denmark
  • Martin Bak Pathology, Odense University Hospital, Odense, Denmark
  • Karen E. Olsen Pathology, Odense University Hospital, Odense, Denmark
  • Dan Kryh From the Departments of Surgery A, Odense, Denmark
  • Vagn Berg From the Departments of Surgery A, Odense, Denmark
  • Christen K. Axelsson From the Departments of Surgery A, Odense, Denmark

DOI:

https://doi.org/10.1080/028418600750013212

Abstract

In a series of 161 consecutive breast cancer operations, intradermal injection of Patent Blue was used to localize the sentinel node (SN). The surgical localization rate was 60%. Including the blue lymph nodes found by the pathologist, localization rate was 70%. After the first 103 operations, the surgical procedure was changed, resulting in a localization rate of 83%. Ten surgeons participated, but only one had previous experience with SN dissection. The others experienced a steep learning curve. Metastasis was found in 42 of 97 SNs (43%). In 15 cases (36%) metastasis was recognized only after step-sectioning and immunohistochemical staining for cytokeratin. In one case a benign epithelial inclusion was found. The sentinel node was false negative in 9.1% of cases. The consensus from the literature is that the best results are achieved using a combination of dye and isotopic techniques.

Downloads

Download data is not yet available.

Downloads

Published

2000-01-01

How to Cite

Ilum, L., Bak, M., Olsen, K. E., Kryh, D., Berg, V., & Axelsson, C. K. (2000). Sentinel Node Localization in Breast Cancer Patients Using Intradermal Dye Injection. Acta Oncologica, 39(3), 423–428. https://doi.org/10.1080/028418600750013212